The place of medical treatment of acromegaly: Current status and perspectives

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 8, 2013, Pages 1001-1015

  Jallad, Raquel S ^a   Bronstein, Marcello D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acromegaly; Dopamine agonists; Medical treatment; Somatostatin analogs; Temozolomid

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; ESTROGEN; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PHOSPHATIDYLINOSITOL 3 KINASE; PROLACTIN; PROTEIN KINASE B; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOSTATIN; STEROID; TEMOZOLOMIDE;

ABDOMINAL CRAMP; ACROMEGALY; ANEMIA; ANTIPROLIFERATIVE ACTIVITY; BLOOD VESSEL INJURY; BODY WEIGHT; BRAIN NECROSIS; CELL PROLIFERATION; CIRCADIAN RHYTHM; CLINICAL PRACTICE; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DISEASE CONTROL; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GALLBLADDER DISEASE; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; HAIR LOSS; HEADACHE; HEALTH CARE PERSONNEL; HEART DISEASE; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HYPERTENSION; HYPOPHYSIS FUNCTION; HYPOPITUITARISM; INJECTION SITE MASS; INJECTION SITE PAIN; INJECTION SITE REACTION; LOADING DRUG DOSE; MALABSORPTION; META ANALYSIS; MOLECULAR PATHOLOGY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PREOPERATIVE TREATMENT; QUALITY OF LIFE; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SINUS BRADYCARDIA; SLEEP DISORDERED BREATHING; TREATMENT DURATION; TUMOR GROWTH; TUMOR RESISTANCE; TUMOR VOLUME; URINARY EXCRETION;

ACROMEGALY; ADENOMA; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; SOMATOSTATIN;

EID: 84877666408     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.784744     Document Type: Review

References (124)

1. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41
2. Kwon O, Song YD, Kim SY, et al. Nationwide survey of acromegaly in South Korea. Clin Endocrinol (Oxf) 2012; [Epub ahead of print]
3. Sesmilo G. Epidemiology of acromegaly in Spain. Endocrinol Nutr 2012;438:S1575-0922
4. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006;91:4769-75
5. Rosario PW, Calsolari MR. Screening for acromegaly by application of a single questionnaire evaluating the enlargement of extremities in adult patients seen at primary healthcare units. Pituitary 2011;15(2):179-83
6. Mercieca C, Gruppetta M, Vassallo J. Epidemiology, treatment trends and outcomes of acromegaly. Eur J Intern Med 2012;23(8):e206-7
7. Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293-9
8. Jenkins D, O'Brien I, Johnson A, et al. The Birmingham pituitary database: Auditing the outcome of the treatment of acromegaly. Clin Endocrinol (Oxf) 1995;43:517-22
9. Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: A retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998;83:2730-4
10. Beauregard C, Truong U, Hardy J, et al. Long-Term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003;58:86-91
11. Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004;89:1613-17
12. Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789-96
13. Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: A metaanalysis. J Clin Endocrinol Metab 2008;93:61-7
14. Giustina A, Chanson P, Bronstein MD, et al. Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95(7):3141-8
15. Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: A structured review and meta-Analysis. Pituitary 2012;15(1):71-83
16. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative Octreotide Treatment of Acromegaly study Group. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-Term postoperative rates: A prospective, randomized trial. J Clin Endocrinol Metab 2008;93(8):2984-90
17. Mao ZG, Zhu YH, Tang HL, et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-Term postoperative cure rates: A prospective, randomised trial. Eur J Endocrinol 2010;162:661-6
18. Li ZQ, Quan Z, Tian HL, Cheng M. Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma. J Int Med Res 2012;40(2):517-24
19. Jallad RS, Musolino NR, Salgado LR, et al. Treatment of acromegaly: Is there still a place for radiotherapy? Pituitary 2007;10(1):53-9
20. Minniti G, Scaringi C, Amelio D, et al. Stereotactic irradiation of GH-secreting pituitary adenomas. Int J Endocrinol 2012;2012:482861
21. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995;16:427-42
22. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98
23. Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46
24. Dasgupta P. Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004;102(1):61-85
25. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003;24:28-47
26. Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 2011;18(6):R233-51
27. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992;21:713-35
28. Weckbecker G, Lewis I, Albert R, et al. Opportunities in somatostatin research: Biological, chemical and therapeutical aspects. Nat Rev Drug Discov 2003;2:999-1017
29. Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone-And prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004;89(4):1577-85
30. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45(8 Suppl 1):67-71
31. Valery C, Pouget E, Pandit A, et al. Molecular origin of the self-Assembly of lanreotide into nanotubes: A multinational approach. Biophys J 2008;94:1782-95
32. Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (oxf) 2005;63:514-19
33. Atonijoan RM, Barbanoj MJ, Cordero JA, et al. Pharmacokinetics of a new autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004;56:471-6
34. Bevan JS, Newell-Price J, Wass JA, et al. Home administration of lanreotide autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 2008;68:343-9
35. Salvatori R, Nachtigall LB, Cook DM, et al. Effectiveness of self-or partner-Administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 2010;13:115-22
36. Colao A, Faggiano A, Pivonello R. Somatostatin analogues: Treatment of pituitary and neuroendocrine tumors. Prog Brain Res 2010;182:281-94
37. Caron P, Bex M, Cullen DR, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 2004;734-40
38. Wuster C, Both S, Cordes U, et al. Primary treatment of acromegaly with high-dose lanreotide: A case series. J Med Case Reports 2010;4:85
39. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: A randomised controlled trial. Eur J Endocrinol 2009;161(2):331-8
40. Ronchi CL, Rizzo E, Lania AG, et al. Preliminary data on biochemical remission of acromegaly after somatostatinanalogs withdrawal. Eur J Endocrinol 2008;158:19-25
41. Ramirez C, Vargas G, Gonzalez B, et al. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: Is it worth trying? Eur J Endocrinol 2012;166(1):21-6
42. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (longacting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 2007;66:859-68
43. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: A randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 2009;70(5):757-68
44. Jallad RS, Musolino NR, Salgado LR, et al. Treatment of acromegaly with octreotide-LAR: Extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 2005;63(2):168-75
45. Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial. Clin Endocrinol (Oxf) 2006;65:320-6
46. Lombardi G, Minuto F, Tamburrano G, et al. Efficacy of the new long-Acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acreomegaly. J Endocrinol Invest 2009;32:202-9
47. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004;150:473-80
48. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: A long-Term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91:1397-403
49. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulation for therapy of acromegaly. J Clin Endocrinol Metab 2008;93:2957-68
50. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-10
51. Maiza JC, Vezzosi D, Matta M, et al. Long-Term (up to 18 years) effects on GH/IGF I hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007;67:282-9
52. Attanasio R, Lanzi R, Losa M, et al. Effects of lanreotide Autogel on growth hormone, insulin like growth factor 1, and tumor size in acromegaly: A 1-year prospective multicenter study. Endocr Pract 2008;14:846-55
53. Colao A, Auriemma RS, Rebora A, et al. Significant tumour shrinkage after 12 months of lanreotide autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 2009;71:237-45
54. Casarini AP, Pinto EM, Jallad RS, et al. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 2006;29(9):826-30
55. Resmini E, Dadati P, Ravetti JL, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-Acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007;92(5):1592-9
56. Ozbek M, Erdogan M, Akbal E, et al. Disappearance of a GH secreting macroadenoma, during long-Term somatostatin analogue administration. Exp Clin Endocrinol Diabetes 2009l;117(7):309-11
57. Auriemma RS, Galdiero M, Grasso LF, et al. Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: Effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. Eur J Endocrinol 2010;162(5):993-9
58. Landolt AM, Haller D, Lomax N, et al. Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 200:85(3):1287-9
59. Pollock BE, Jacob JT, Brown PD, et al. Radiosurgery of growth hormone-producing pituitary adenomas: Factors associated with biochemical remission. J Neurosurg 2007;5):833-8
60. Jagannathan J, Sheehan JP, Pouratian N, et al. Gamma knife radiosurgery for acromegaly: Outcomes after failed transsphenoidal surgery. Neurosurgery 2008;62(6):1262-9.discussion 1269-70
61. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: A 4-year follow-up study. J Clin Endocrinol Metab 2003;88:3105-12
62. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of Gamma knife radiosurgery in 82 patients with acromegaly: Correlation with initial hypersecretion. J Clin Endocrinol Metab 2005;90:4483-8
63. Gola M, Bonadonna S, Mazziotti G, et al. A Resistance to somatostatin analogs in acromegaly: An evolving concept? J Endocrinol Invest 2006;29:86-93
64. Colao A, Auriemma RS, Lombardi G, et al. Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011;32(2):247-71
65. Ballare E, Persani L, Lania AG, et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001;86:3809-14
66. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: A randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010;95:2781-9
67. Petersenn S, Unger N, Hu K, et al. Pasireotide (SOM230), a novel multi-receptor-Targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J Clin Pharmacol 2012;7):1017-27
68. van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004;89:638-45
69. Bronstein MD, Sheppard M, Freda P, et al. Pasireotide LAR is significantly more effective than octreotide LAR at providing biochemical control in patients with acromegaly: Results of a 12-month randomized, double-blind, multicenter, phase III study. Endocr Rev 2012;33(03- MeetingAbstracts):OR49-3
70. Sheppard M, Gadelha M, Bronstein MD, et al. A pasireotide LAR and octreotide LAR maintain biochemical control in patients with acromegaly: Extension phase of a 12-month randomized, double-blind, multicenter, phase III study. Endocr Rev 2012;33(03-MeetingAbstracts):SUN-738
71. Fleseriu M, Sheppard M, Bronstein MD, et al. Witching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: Crossover extension to a randomized, double-blind, multicenter, phase III study. Endocr Rev 2012;33(03-MeetingAbstracts):SUN-741
72. Mazziotti G, Floriani I, Bonadonna S, et al. Effects of somatostatin analogues on glucose homeostasis: A metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94:1500-8
73. Wahid ST, Marbach P, Stolz B, et al. Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: The role of SST receptor desensitisation and circulating antibodies to SST analogues. Eur J Endocrinol 2002;146(3):295-302
74. Jaquet P. CV 205-502: A more effective dopamine agonist m the treatment of acromegaly? Eur J Endocrinol 1995;132:557-8
75. Lombardi G, Colao A, Ferone D, et al. CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol 1995;132:559-64
76. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: A meta-Analysis. J Clin Endocrinol Metab 2011;96:1327-35
77. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: A study in 64 patients. J Clin Endocrinol Metab 1998;83(2):374-8
78. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356(1):39-46
79. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiacvalve regurgitation. N Engl J Med 2007;356(1):29-38
80. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfl uramine and other serotonergic medications. Circulation 2000;102(23):2836-41
81. Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005;513(3):225-8
82. Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly. Endocr Rev 2002;23(5):623-46
83. Higham CE, Thomas JD, Bidlingmaier M, et al. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 2009;161(1):21
84. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171-7
85. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-Term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358(9295):1754-9.60
86. van der Lely AJ, Biller BM, Brue T, et al. Long-Term safety of pegvisomant in patients with acromegaly: Comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012;97(5):1589-97
87. Marazuela M, Lucas T, Alvarez-Escola C, et al. Long-Term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: Its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 2009;160(4):535-42
88. Ghigo E, Biller BM, Colao A, et al. Comparison of pegvisomant and long-Acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest 32:924-33.2009
89. Buchfelder M, Weigel D, Droste M, et al. Pituitary tumor size in acromegaly during pegvisomant treatment: Experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 2009;161(1):27-35l
90. Marazuela M, Paniagua AE, Gahete MD, et al. Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study. J Clin Endocrinol Metab 2011;96(2):E251-9
91. Bonert VS, Kennedy L, Petersenn S, et al. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008;93:3515-18
92. Buyuktas D, Celik O, Kantarci F, et al. Lipodystrophy during pegvisomant therapy: A case report and review of the literature. Clinics (Sao Paulo) 2010;65(9):931-3; Review
93. Minniti G, Jaffrain-Rea ML, Baldelli R, et al. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients. Clin Ter 1997;12:601-7
94. Marzullo P, Ferone D, Di Somma C, et al. Efficacy of combined treatment with lanreotide and cabergoline inselected therapy-resistant acromegalic patients. Pituitary 1999;2:115-20
95. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61:209-15
96. Gatta B, Hau DH, Catargi B, et al. Reevaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients Clin Endocrinol (Oxf) 2005;63:477-8
97. Selvarajah D, Webster J, Ross R, et al. Effectiveness of adding dopamine agonist therapy to long-Acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005;152:569-74
98. Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: Beneficial effects of cabergoline in patients uncontrolled with long-Acting release octreotide. Neuroendocrinology 2009;90:82-92
99. Mattar P, Alves Martins MR, Abucham J. Short-And long-Term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly. Neuroendocrinology 2010;92:120-7
100. Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 2011;14(2):148-56
101. Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: A retrospective clinical study and review of theliterature. Endocr J 2013; [Epub ahead of print]
102. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005;90(10):5627-31
103. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365(9471):1644-6
104. Neggers SJ, de Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long acting somatostatin analogs and pegvisomant: Long-Term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009;4):529-33
105. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-Term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;10):3853-9
106. Bernabeu I, Alvarez-Escola C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary. 2012; [Epub ahead of print]
107. Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: A prospective clinical trial. J Clin Endocrinol Metab 2012;97(4):1187-93
108. Jallad RS, Musolino NR, Kodaira S, et al. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 2007;67(2):310-15
109. Teichman SL, Tuvia S, Atsmon J, et al. Pharmacodynamics: An oral octreotide formulation to treat acromegaly suppresses growth hormone in healthy volunteers. Endocr Rev 2012;33:OR49-4
110. Tuvia S, Kramer WG, Pelled D, et al. Pharmacokinetic modeling of oral octreotide (Octreolin™) in healthy volunteers and dosing regimen optimization for acromegaly patients. Endocr Rev 2012;33:OR29-6
111. Kam GY, Leung KC, Baxter RC, et al. Estrogens exert route and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin Endocrinol Metab 2000;85:1918-22
112. Karjalainen A, Paassilta M, Heikkinen J, et al. Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism. Clin Endocrinol (Oxf) 2001;54:165-73
113. Leung KC, Johannsson G, Leong GM, et al. Estrogen regulation of growth hormone action. Endocr Rev 2004;25:693-721
114. Shimon I, Barkan A. Estrogen treatment for acromegaly. Pituitary 2012;15(4):601-7
115. Ortiz LD, Syro LV, Scheithauer BW, et al. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 2012;67(Suppl 1):119-23
116. Hagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009;161:631-7
117. Morin E, Berthelet F, Weisnagel J, et al. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 2012;15(1):97-100
118. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001;114:1439-45
119. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004
120. Zatelli MC, Minoia M, Filieri C, et al. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2010;95:968-76
121. Gorshtein A, Rubinfeld H, Kendler E, et al. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH secreting pituitary tumor cells in vitro. Endocr Relat Cancer 2009;16:1017-27
122. Cerovac V, Monteserin-Garcia J, Rubinfeld H, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010;70:666-74
123. Thimmaiah KN, Easton J, Huang S, et al. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3¢-kinase-Akt signaling pathways. Cancer Res 2003;63(2):364-74
124. Villaume K, Blanc M, Gouysse G, et al. VEGF secretion by neuroendo:crine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/Akt/mTOR pathway. Neuroendocrinology 2010;91(3):268-78